As a novel, patient-specific treatment, the practical implementation of chimeric antigen receptor (CAR) T-cell therapy poses unique challenges. From the Oncology Nursing Society (UKONS) 2018 Annual Conference, held in Glasgow, UK, David Irvine, MBChB, PhD, from the University of Glasgow, Glasgow, UK, outlines the need for innovative new approaches to effectively address these challenges, before explaining the importance of co-operation between healthcare professionals in ensuring governance and patient safety.